{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T05:31:40Z","timestamp":1739338300645,"version":"3.37.0"},"reference-count":42,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Angiol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myocardial infarction is the permanent death (necrosis) of heart muscle caused by a lack of oxygen for an extended period of time (ischemia). Since the very first percutaneous transluminal coronary angioplasty was done 40 years ago, the science of interventional cardiology has advanced dramatically. The above progression began with a balloon catheter attached to a fixed wire, advancing to bare-metal stents, first-generation drug-eluting stents (DES), second- and third-generation biodegradable polymer-based DES. Ultimately, bioabsorbable stents are still in development. Zotarolimus is a new pharmacologic therapy with a similar reprint address; for example, the antirestenosis agent sirolimus has recently been investigated as part of a stent platform combined with a biomimetic phosphorylcholine and BioLINX polymer for its biological activity, as well as its usefulness as an antiproliferative agent. Several clinical trials have been conducted to assess the safety and efficacy of the zotarolimus drug-eluting stent (Z-DES). Medtronic Medical Devices, a global leader in medical technology (United States), and Abbot Global Health Care and Research began clinical trials on the Z-DES in 2002 and will continue through 2021 (INDIA). Endeavor (E-Zes), Resolute (R-Zes), Resolute Integrity (I-Zes), and Resolute Onyx are the different forms of Z-DES that Medtronic has tested in clinical trials. In comparison to other DES, Z-DES was found to be safe in these clinical trials done across multiple nations and in a diverse demographic. This review helps understand the overall clinical trial of Z-DES.<\/jats:p>","DOI":"10.1055\/s-0044-1791556","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T23:14:38Z","timestamp":1729552478000},"page":"023-032","source":"Crossref","is-referenced-by-count":0,"title":["A Snapshot on Clinical Trials on Zotarolimus DES: A Repurposing Drug against Myocardial Infarction"],"prefix":"10.1055","volume":"34","author":[{"given":"Vaishali R.","family":"Undale","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Savitribai Phule Pune University, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shweta K.","family":"Lembhe","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Savitribai Phule Pune University, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shital D.","family":"Satone","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Savitribai Phule Pune University, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratiksha","family":"Hase","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Savitribai Phule Pune University, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2217\/fca-2017-0091","article-title":"Safety and effectiveness of zotarolimus-eluting stents for percutaneous coronary intervention: a systematic review","volume":"14","author":"J X Yang","year":"2018","journal-title":"Future Cardiol"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"3A","DOI":"10.1016\/j.amjcard.2009.10.007","article-title":"Cardiovascular disease risk factors: epidemiology and risk assessment","volume":"105","author":"B Dahl\u00f6f","year":"2010","journal-title":"Am J Cardiol"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11886-015-0681-x","article-title":"The history of primary angioplasty and stenting for acute myocardial infarction","volume":"18","author":"N R Smilowitz","year":"2016","journal-title":"Curr Cardiol Rep"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(17)31927-X","article-title":"Coronary balloon angioplasty, stents, and scaffolds","volume":"390","author":"R A Byrne","year":"2017","journal-title":"Lancet"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/jpm8040033","article-title":"40 Years of percutaneous coronary intervention: history and future directions","volume":"8","author":"J Canfield","year":"2018","journal-title":"J Pers Med"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jcin.2016.11.004","article-title":"5-Year safety and efficacy of resolute zotarolimus-eluting stent: The RESOLUTE Global Clinical Trial Program","volume":"10","author":"R W Yeh","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"issue":"13","key":"ref7","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1056\/NEJMoa1607991","article-title":"Drug-eluting or bare-metal stents for coronary artery disease","volume":"375","author":"K H B\u00f8naa","year":"2016","journal-title":"N Engl J Med"},{"issue":"03","key":"ref8","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1755-5922.2010.00144.x","article-title":"Current status of drug-eluting stents","volume":"29","author":"L R\u00e4ber","year":"2011","journal-title":"Cardiovasc Ther"},{"issue":"13","key":"ref9","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1056\/NEJMoa1910021","article-title":"Polymer-based or polymer-free stents in patients at high bleeding risk","volume":"382","author":"S Windecker","year":"2020","journal-title":"N Engl J Med"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1586\/14779072.2016.1112267","article-title":"Drug-eluting stents to prevent stent thrombosis and restenosis","volume":"14","author":"E Im","year":"2016","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1540-8183.2006.00184.x","article-title":"Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent","volume":"19","author":"D E Kandzari","year":"2006","journal-title":"J Interv Cardiol"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1004130","article-title":"Comparison of zotarolimus-eluting and everolimus-eluting coronary stents","volume":"363","author":"P W Serruys","year":"2010","journal-title":"N Engl J Med"},{"issue":"21","key":"ref13","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2013.08.725","article-title":"Stent thrombosis with drug-eluting stents: is the paradigm shifting?","volume":"62","author":"T Palmerini","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1161\/CIRCINTERVENTIONS.110.960872","article-title":"Stent: the man and word behind the coronary metal prosthesis","volume":"4","author":"A Roguin","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"issue":"7398","key":"ref15","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1136\/bmj.326.7398.1080","article-title":"ABC of interventional cardiology: percutaneous coronary intervention. I: history and development","volume":"326","author":"E D Grech","year":"2003","journal-title":"BMJ"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/bmb\/ldt009","article-title":"Coronary stents: historical development, current status and future directions","volume":"106","author":"J Iqbal","year":"2013","journal-title":"Br Med Bull"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJM198703193161201","article-title":"Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty","volume":"316","author":"U Sigwart","year":"1987","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"36M","DOI":"10.1016\/j.amjcard.2007.08.020","article-title":"The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents","volume":"100","author":"G Nakazawa","year":"2007","journal-title":"Am J Cardiol"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cjca.2013.09.012","article-title":"The evolution of coronary stents: a brief review","volume":"30","author":"T Simard","year":"2014","journal-title":"Can J Cardiol"},{"issue":"08","key":"ref20","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2014.11.053","article-title":"Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates","volume":"65","author":"M Valgimigli","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/FJC.0b013e3180325b0a","article-title":"Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression","volume":"49","author":"Y-W Chen","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"volume-title":"Braunwald's Heart Disease E-Book: A Textbook of Cardiovascular Medicine","year":"2011","author":"R O Bonow","key":"ref22"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.addr.2006.01.021","article-title":"Zotarolimus (ABT-578) eluting stents","volume":"58","author":"S E Burke","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"56M","DOI":"10.1016\/j.amjcard.2007.08.023","article-title":"Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study","volume":"100","author":"I T Meredith","year":"2007","journal-title":"Am J Cardiol"},{"issue":"01","key":"ref27","first-page":"76","article-title":"Safety of direct stenting with the Endeavor stent: results of the Endeavor II continued access registry","volume":"3","author":"H P Schultheiss","year":"2007","journal-title":"EuroIntervention"},{"issue":"12","key":"ref28","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jcin.2009.10.009","article-title":"Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)","volume":"2","author":"E L Eisenstein","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jcin.2012.12.123","article-title":"The \u201cfinal\u201d 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent","volume":"6","author":"A J Kirtane","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"issue":"12","key":"ref30","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jcin.2009.10.001","article-title":"Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry","volume":"2","author":"C Lotan","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"issue":"12","key":"ref31","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jcin.2015.07.018","article-title":"Post-Percutaneous Coronary Intervention Angina: A New Performance Measure?","volume":"8","author":"R Tavella","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"issue":"07","key":"ref32","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jcin.2015.01.033","article-title":"Clinical events and patient-reported chest pain in all-comers treated with Resolute Integrity and Promus Element stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II)","volume":"8","author":"H Sen","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"issue":"05","key":"ref33","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jcin.2017.11.031","article-title":"5-Year outcome following randomized treatment of all-comers with zotarolimus-eluting resolute integrity and everolimus-eluting PROMUS element coronary stents: Final Report of the DUTCH PEERS (TWENTE II) Trial","volume":"11","author":"P Zocca","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"issue":"04","key":"ref34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/17434440.2020.1736037","article-title":"Device profile of the Resolute Onyx zotarolimus eluting coronary stent system for the treatment of coronary artery disease: overview of its safety and efficacy","volume":"17","author":"M Blum","year":"2020","journal-title":"Expert Rev Med Devices"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/0300060517717826","article-title":"One-year clinical outcomes of patients implanted with a Resolute Onyx\u2122 zotarolimus-eluting stent","volume":"46","author":"C C Tam","year":"2018","journal-title":"J Int Med Res"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ccd.27322","article-title":"Safety and efficacy of the next generation Resolute Onyx zotarolimus-eluting stent: primary outcome of the RESOLUTE ONYX core trial","volume":"92","author":"M J Price","year":"2018","journal-title":"Catheter Cardiovasc Interv"},{"issue":"04","key":"ref37","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s11096-018-0693-x","article-title":"Pharmacovigilance in China: development and challenges","volume":"40","author":"Y Zhao","year":"2018","journal-title":"Int J Clin Pharm"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0140-6736(18)32001-4","article-title":"Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial","volume":"392","author":"C von Birgelen","year":"2018","journal-title":"Lancet"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ahj.2019.04.017","article-title":"Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1\u202fmonth of dual antiplatelet therapy","volume":"214","author":"E Kedhi","year":"2019","journal-title":"Am Heart J"},{"issue":"02","key":"ref40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/FJC.0b013e31825aa742","article-title":"Comparative assessment of transient exposure of paclitaxel or zotarolimus on in vitro vascular cell death, proliferation, migration, and proinflammatory biomarker expression","volume":"60","author":"D S Steinfeld","year":"2012","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref41","first-page":"26","volume-title":"Second-Generation Drug-Eluting Stents: Moving the Field Forward","author":"F Alfonso","year":"2011"},{"issue":"01","key":"ref42","first-page":"1","article-title":"Third generation drug eluting stent (DES) with biodegradable polymer in diabetic patients: 5 years follow-up","volume":"16","author":"M Wiemer","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"07","key":"ref43","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.hlc.2013.02.008","article-title":"New generation coronary stent technology\u2014is the future biodegradable?","volume":"22","author":"A M Sammel","year":"2013","journal-title":"Heart Lung Circ"},{"issue":"03","key":"ref44","first-page":"367","article-title":"Percutaneous coronary intervention, a historical perspective looking to the future","volume":"5","author":"J Bennett","year":"2013","journal-title":"J Thorac Dis"}],"container-title":["International Journal of Angiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1791556.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:28:48Z","timestamp":1739320128000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1791556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":42,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2025,2,11]]},"published-print":{"date-parts":[[2025,3]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1791556","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1061-1711","1615-5939"],"issn-type":[{"type":"print","value":"1061-1711"},{"type":"electronic","value":"1615-5939"}],"subject":[],"published":{"date-parts":[[2024,10,21]]}}}